Article

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

2023-03-15

Abstract excerpt

<h4>ABSTRACT</h4> Although high-dose, multi-agent chemotherapy has improved leukemia survival rates in recent years, treatment outcomes remain poor in high-risk subsets, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in infants. Development of new, more effective therapies for these patients is therefore an urgent, unmet clinical need. To address this challenge, we developed a nanos...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e121143a-cd80-5c1f-abb2-c5a6130a3865
DOI: 10.1101/2023.03.13.531236

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AMLDOI 10.1101/2023.03.13.531236Read

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic LeukemiaSemantic proximity Read

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid LeukemiaSemantic proximity Read

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Semantic proximity Read

Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expressionSemantic proximity Read

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia: Computational target analysis and therapeutic validationSemantic proximity Read

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia modelsSemantic proximity Read

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read

Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid LeukemiaSemantic proximity Read

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read

Combined venetoclax and alvocidib in acute myeloid leukemiaSemantic proximity Read

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell linesSemantic proximity Read